pre-miRNA Information | |
---|---|
pre-miRNA | mmu-mir-143 |
Genomic Coordinates | chr18: 61649196 - 61649258 |
Synonyms | Mirn143, mmu-mir-143, Mir143 |
Description | Mus musculus miR-143 stem-loop |
Comment | Expression of this miRNA in mouse was independently verified in heart and brain . |
RNA Secondary Structure |
Mature miRNA Information | |
---|---|
Mature miRNA | mmu-miR-143-3p |
Sequence | 40| UGAGAUGAAGCACUGUAGCUC |60 |
Evidence | Experimental |
Experiments | Cloned |
Putative Targets |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | Zfp488 | ||||||||||||||||||||
Synonyms | Gm1206, Znf488 | ||||||||||||||||||||
Description | zinc finger protein 488 | ||||||||||||||||||||
Transcript | NM_001013777 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on Zfp488 | |||||||||||||||||||||
3'UTR of Zfp488 (miRNA target sites are highlighted) |
>Zfp488|NM_001013777|3'UTR 1 CAGGTGGCTACAGAGGAAACCGATGGCCATAGTATCCAGGACACAGTGGTGAGGCACAGGTGACTACCGGCCTTTGCTGA 81 GAAGGTTGTCATAGACTTCTTCAAGGTTGTTCCTTTTGCTTCCCAGACATGAACTGCTCAGTTATAATTTGTCAGGTGTC 161 CCAGGCCTCGTGATGTGTTTAATGCACAATATGTTTAGTCATGCATTAAAGTGATAAGCTTCACTCATGGGATAGTGGGA 241 CCCATGGCTCAGGGAACAGGGCTGCTCCTGTCTCTGTCCCCAGTACTCTGCAAGGAAGCACATGAGTATGACATCGTGGC 321 TTTGCTGATGAGCAAGCCTGCACTCAATCTATGCTTTCAACTATGAGCCCTGACCTCGGACCTGTTCCTTTAGCTTGCTG 401 AACCTCACTTTTATTTTGAAAGTGGTGTGTTAGCAGGATGTCATCAGAGTGGCCCGCTTATTCCCTGGTTGACTGTGAGC 481 ATTAAGCATATGGATTGTATAGTCACTGCTTGCACTAGCCAGCTACGTCATTCATGAAATCTCAGGGATGAACAAACATT 561 GTGTTTCTCTGCCACAAGGCTGGGGATGGCTTGGTGGACATAGCTCAAGCTGCACTCAAGTCTAGGCCCTTTTGCTGCTG 641 GGTCATTATGCTGGATATAGTGAAGCCCAGAGTGGAAAATACCGAGAAAATGGGTCACAAGCCTAAGTTTCCCTGGCCCT 721 ACGTAAATCCAGGCCTAAAGGGGCCGAGTGAAAAAGTGACCTGGCTGAAACCCTAACAAAGGAGTGGGGGCTAGTAATAC 801 AGCTCCCCCCATTCTCTGGGTATTCACACTGTGAATGTGTGAGAAGAGAGAAACAGAACACACATCATTTATTCTGGATT 881 TTATCCAGGTGCCATTCATCCTTGTGGTTCTGAGTAGGGCAGGAAAGAGCAAGTGGAGGGTCCTCGGAATGAGGTCCCCA 961 GGCGGCACTTCACATCCTCTCATCTGTAGGACACAGACAGTGAATTCTCATCCTACTGCAGATGAATTTCAACTTAAAAA 1041 GGCTATTGACTTTCCCAACACCACTTTGTCAGGAGCATTGGTGGAAGAACAAAATCCCATGAAGCCCCAGATCTGAGCTC 1121 AGGTCTTTCCAGCCGCTTCATGTCTGCTTAGCTAGCATGGCCATGGAGCGTACTAAGTGACTCAAGGTCTGGAACTTTGA 1201 GGCTGGGCTCCTTAAGTTCAATTCCAACTTAACCTTGCTACTTTACAAGACGTACACGTGCTCATGCACGCGCATGTGCA 1281 CACACACACACACACACACACACACACACACACACACACACACCACTCTTCTCTTGAGCACTTTTCTCCATCTTGTATAC 1361 TAAATAGCATAGCGACTTATCCTGTCCACTGTAGCTCTCCTCTCTAGAATAAAAGGGAGTTTTGGTGTATTTCCATCATC 1441 TAGAACAACACAGACACTCAACAGGTATCTGTTGAAAGAAAGAATAAACACATAAGTTAACAAATGAACGATCTGCCTGA 1521 CTCTGGCTTTGCTCCTGCCAACTCTTGAGTTGGCTTTGAGGAACAAGAGGTGGCATCTGTCAAAAGCACACTTACCTTGA 1601 GCCCACACATTGGCACTGATTTCTATGCCATCTCTTTGGAAAGGGGAATGGTCCTGTCATAGCATACAGAAGATGCTTAG 1681 AATTGATGTTGACACAAGTTGCTTTGCAGCCAGATTTACAAGTTCAAAGATGTTTAAAAGCCGGTGACTTAGGACTTGTT 1761 AGTGACACAGTCCCTCAGAATAAGCATGCTGGGTTCCCAGGTGTCCTCTGGAAGTCCCACCCCCTCTCCTGTCTCCCTTC 1841 TTCATGCCACTTGCTCCTCCCAGCGAGAAGGCACTTTATTTTTATTTTATTTTTATATTTTTCCATTTTTTATTAGGTAT 1921 TTAGCTCATTTACATTTCCAATGTTATACCAAAAGTCCCCCACAGCCACCCACCCCCACTCCCCTACCCACCCACTCCCC 2001 CTTTTTGGCCCTGGCGTTCCCCTGTACTGGGGCATATAAAGTTTGCAAGTCCAATGGGCCTCTCTTTCCAGTGATGGCCG 2081 ACTAGGCCATCTTTTGATACATATGCAGCTAGAGTCAAGAGCTCCGGGGTACTGGTTAGTTCATTATGTTGTTCCACCTA 2161 TAGGGTTGCAGATCCCTTTAGCTCCTTGGCTACTTTCTCTAGCTCCTCCATTGGGAGCCCTGTGATTCATCCATTAGCTG 2241 ACTGTGAGCATCCACTTCTGTGTTTGCTAGGCCCCGGCATAGTCTCACAAGAGACAGCTACATCTGGGTCCTTTCAATAA 2321 AATCTTGCTAGTGTATGCAATGGTCTCAGCGTTTGGAAGCTGATTATGGGGTGGATCCCTGGATATGGCAGTCTCTACAT 2401 GGTCCATCCTTTCATCTCAGCTCCAAACTTTGTCTCTGTAACTCCTTCCATGGGTGTTTTGTTCCCAATTCTAAGGAGGG 2481 GCATAGTGTCCACACTTCAGTCTTCATTCTTCTTGAGTTTCATGTGTTTAGCAAATTGTATCTTATATCTTGGGTATCCT 2561 AGGTTTGGGGCTAATATCCACTTATCAGTGAGTACATATTGTGTGAGTTCCTTTGTGATTGTGTTACCTCACTCAGGATG 2641 ATGCCCTCCAGGTCCATCCATTTGGCTAGGAATTTCATAAATTCATTCTTTTTAATAGCTGAGTAGTACTCCATTGTGTA 2721 GATGTACCACATTTTCTGTATCCATTCCTCTGTTGAGGGGCATCTGGGTTCTTTCCAGCTTCTGGCTATTATAAATAAGG 2801 CTGCTATGAACATAGTGGAGCATGTGTCGAGAAGGCACTTTAAACCATGACTTCCCAACTTAGGTCTTTCATTAAATAAA 2881 TAAAAAAAATAGTCTGGATATTTTTGTTTTTCAAAATTTATGTGAAAATTCTAAGGTGGGCCGTTATGAGATTGGGACTG 2961 ATGCTTTATGGGTTCTAGAGGGCAAGCTCCTCACTGTCTCTCTGAAGACGCAGCTAAAAAGAGCAATCTCTGAACTAGAA 3041 AATGGCCCTCACGAGAGACATTACATCTGCATACACACGACCCCTTTATGATCCAGAACAATAAATTCCTGTTGTTTATA 3121 AAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | mESCs |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM622574. RNA binding protein: AGO2. Condition:KO2
... - Leung AK; Young AG; Bhutkar A; Zheng GX; et al., 2011, Nature structural & molecular biology. |
Article |
- Leung AK; Young AG; Bhutkar A; Zheng GX; et al. - Nature structural & molecular biology, 2011
MicroRNAs (miRNAs) are 19-22-nucleotide noncoding RNAs that post-transcriptionally regulate mRNA targets. We have identified endogenous miRNA binding sites in mouse embryonic stem cells (mESCs), by performing photo-cross-linking immunoprecipitation using antibodies to Argonaute (Ago2) followed by deep sequencing of RNAs (CLIP-seq). We also performed CLIP-seq in Dicer(-)/(-) mESCs that lack mature miRNAs, allowing us to define whether the association of Ago2 with the identified sites was miRNA dependent. A significantly enriched motif, GCACUU, was identified only in wild-type mESCs in 3' untranslated and coding regions. This motif matches the seed of a miRNA family that constitutes ~68% of the mESC miRNA population. Unexpectedly, a G-rich motif was enriched in sequences cross-linked to Ago2 in both the presence and absence of miRNAs. Expression analysis and reporter assays confirmed that the seed-related motif confers miRNA-directed regulation on host mRNAs and that the G-rich motif can modulate this regulation.
LinkOut: [PMID: 21258322]
|
24 mmu-miR-143-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT004492 | Prkce | protein kinase C, epsilon | 4 | 1 | ||||||||
MIRT004532 | Vcan | versican | 4 | 1 | ||||||||
MIRT004772 | Elk1 | ELK1, member of ETS oncogene family | 4 | 1 | ||||||||
MIRT006031 | Kras | Kirsten rat sarcoma viral oncogene homolog | 5 | 1 | ||||||||
MIRT006032 | Rreb1 | ras responsive element binding protein 1 | 5 | 1 | ||||||||
MIRT006121 | Ptn | pleiotrophin | 3 | 1 | ||||||||
MIRT054755 | Igfbp5 | insulin-like growth factor binding protein 5 | 2 | 1 | ||||||||
MIRT586427 | Ogfrl1 | opioid growth factor receptor-like 1 | 1 | 1 | ||||||||
MIRT589192 | Ptpn3 | protein tyrosine phosphatase, non-receptor type 3 | 1 | 1 | ||||||||
MIRT591160 | Myo5c | myosin VC | 1 | 1 | ||||||||
MIRT593574 | Zyg11b | zyg-ll family member B, cell cycle regulator | 1 | 1 | ||||||||
MIRT594328 | Nav1 | neuron navigator 1 | 1 | 1 | ||||||||
MIRT595606 | Mapk8 | mitogen-activated protein kinase 8 | 1 | 1 | ||||||||
MIRT596433 | Crebzf | CREB/ATF bZIP transcription factor | 1 | 1 | ||||||||
MIRT596597 | Zfp488 | zinc finger protein 488 | 1 | 1 | ||||||||
MIRT599868 | Acnat1 | acyl-coenzyme A amino acid N-acyltransferase 1 | 1 | 1 | ||||||||
MIRT600661 | March5 | membrane-associated ring finger (C3HC4) 5 | 1 | 1 | ||||||||
MIRT602320 | Gas2l3 | growth arrest-specific 2 like 3 | 1 | 1 | ||||||||
MIRT604071 | Egln2 | egl-9 family hypoxia-inducible factor 2 | 1 | 1 | ||||||||
MIRT731148 | Dnmt3a | DNA methyltransferase 3A | 1 | 1 | ||||||||
MIRT733322 | Sox2 | SRY (sex determining region Y)-box 2 | 2 | 0 | ||||||||
MIRT734441 | Map3k7 | mitogen-activated protein kinase kinase kinase 7 | 2 | 0 | ||||||||
MIRT735453 | COL5A2 | collagen type V alpha 2 chain | 1 | 0 | ||||||||
MIRT756168 | Npy | neuropeptide Y | 2 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|